Monsanto: Anderson must uproot Bayer’s perennial problem - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT商学院

Monsanto: Anderson must uproot Bayer’s perennial problem

New chief needs to signal to investors whether a restructuring is likely

Bayer’s 2018 acquisition of US crop science company Monsanto is the takeover that just keeps on taking. This week’s €2.5bn impairment charge adds to already extensive financial damage. It will reinvigorate activist demands for a break-up.

Bayer paid $65bn for Monsanto assets that included a glyphosate weedkiller called Roundup. Management initially underestimated the high cost of an accompanying health scare, as managements typically do. Allegations that Roundup is carcinogenic have prompted numerous lawsuits.

Bayer trades at a depressed enterprise valuation of about 7 times forward ebitda. Change may now be in the air. Werner Baumann, the chief executive responsible for the Monsanto purchase, has stepped aside after a long period of poor share price performance. Replacement Bill Anderson started last month. As a former Roche executive, his expertise is drugs, not weedkillers.

A couple of things look odd about the impairment. First, it is relatively small, given that Bayer has about €39bn of goodwill on its balance sheet, more than half of which derives from the Monsanto acquisition. Second, Bayer blames a weak glyphosate market, which might be a temporary phenomenon, for the writedown. About 60 per cent of world sales are generic products, most of which are made in China.

Anderson will hopefully substitute signal for noise when he presents earnings on August 8. He should signal whether a restructuring is likely. Activists Inclusive Capital and Bluebell have called for this. They favour a spinout of the crop science unit, a business that troubles environmental, social and governance investors.

That would make sense. Even at 10 times next year’s ebitda, a sixth cheaper than rivals FMC and Corteva, Bayer’s crop science unit should be worth about €60bn, 2024 Visible Alpha estimates imply — albeit undiscounted for a long tail of legal claims. Compare that with the group’s total enterprise value of €86bn.

Bayer has argued that cash flow from crop science and its consumer health unit help fund its growing pharmaceuticals pipeline. But Bayer’s persistently low multiple against agrochemical and pharma peers underscores the need for change.

Anderson wishes to boost pharma, for example, by removing centralised research budgeting. But that could take years to lift the group’s low valuation. Like all incoming bosses, he has a brief window to cut loose a problem division. He should exploit it.

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

华尔街对大型科技公司2000亿美元的人工智能支出感到担忧

本周,美国四大互联网集团的AI效益初现端倪,但也警告说将增加支出。

地中海已经变成危险的“汽油桶”了吗?

暴雨的部分原因是海水温度的危险上升。

从错失的投资机会中得到的教训

我是如何错过OpenAI、BrewDog和英国电信的?

决定特朗普贸易政策的内部竞争

在这位共和党候选人的第一个总统任期,其政府内部内斗不断。

政府顾问表示,英国应简化人工智能专家的签证程序

马特•克利福德关于促进科技产业发展的建议还包括设立数据中心特区。

为什么卡玛拉•哈里斯会赢

因为这仍然是经济问题,傻瓜。
设置字号×
最小
较小
默认
较大
最大
分享×